Abstract

Therapy of the patient suffering bipolar disorder requires continuation beyond the acute phases to prevent new episodes. The objective of this non-systematic review is to analyze the role of antipsychotic drugs in long-term therapy of bipolar disorder. Clinical practice guidelines (CPG) published between 2009 and 2014 have been reviewed. Several atypical antipsychotic drugs (aripiprazole, olanzapine, quetiapine, long-acting risperidone, and ziprasidone) are recommended, as monotherapy or combined with a mood-stabilizing drug, as first line long-term treatment in several CPG. Most drugs have an indication for prevention of manic episodes, and only quetiapine is recommended to prevent depressive episodes as well. Considering long-term treatment of bipolar disorder with antipsychotic drugs is adequate, but risk/benefit ratio of these drugs has to be kept in mind, given the limitations of available studies and the possible side effects of prolonged treatment.

Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call